Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator of HR(-)/HER2(+) tumors, eliciting tumor dependency in these cells. Mechanistically, HR(-)/HER2(+) cells secrete high levels of the interleukin-6 (IL-6) cytokine, inducing the activation of STAT3, which in turn promotes a second autocrine stimulus to increase S100A8/9 complex (calprotectin) production and secretion. Increased calprotectin levels activate signaling pathways involved in proliferation and resistance. Importantly, we demonstrated that inhibition of the IL-6-Janus kinase 2 (JAK2)-STAT3-calprotectin axis with FDA-approved drugs, alone and in combination with HER2 inhibitors, reduced the tumorigenicity of HR(-)/HER2(+) breast cancers, opening novel targeted therapeutic opportunities.

[1]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[2]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[3]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[4]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[5]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[6]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[7]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[8]  J. Turkson,et al.  Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. , 2010, Cancer research.

[9]  S. Dave,et al.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.

[10]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[11]  Mariano J. Alvarez,et al.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.

[12]  N. Hacohen,et al.  Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[13]  Andrea Califano,et al.  Pooled shRNA screenings: computational analysis. , 2013, Methods in molecular biology.

[14]  J. Niland,et al.  Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study , 2012, Breast Cancer Research.

[15]  T. DeWeese,et al.  Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts , 2012, The Prostate.

[16]  H. Kawai,et al.  Prognostic impact of S100A9 overexpression in non-small cell lung cancer , 2011, Tumor Biology.

[17]  P. Musiani,et al.  Stat3 is required for anchorage‐independent growth and metastasis but not for mammary tumor development downstream of the ErbB‐2 oncogene , 2009, Molecular carcinogenesis.

[18]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[19]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[20]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[21]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[22]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[23]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[24]  J. Singh,et al.  Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. , 2012, Clinical therapeutics.

[25]  Jayanta Debnath,et al.  The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.

[26]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[27]  A. Yosepovich,et al.  Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients , 2009, American journal of clinical oncology.

[28]  Yasuhiro Ito,et al.  S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.

[29]  R. Rodríguez-Barrueco,et al.  Pooled shRNA screenings: experimental approach. , 2013, Methods in molecular biology.

[30]  R. Hoffman,et al.  Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis , 2012, Clinical Cancer Research.

[31]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.

[32]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[33]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[34]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[35]  M. Campiglio,et al.  HER2 as a target for breast cancer therapy , 2010, Expert opinion on biological therapy.

[36]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[37]  E. Dreher,et al.  EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. , 2001, International journal of oncology.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[39]  M. Sakaguchi,et al.  S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. , 2013, Cancer research.

[40]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[41]  J. Vadgama,et al.  STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits , 2013, International journal of oncology.

[42]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[43]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[44]  D. Mayer,et al.  S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. , 2006, Experimental cell research.

[45]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[46]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[47]  G. Baldassarre.  Faculty Opinions recommendation of Molecular portraits of human breast tumours. , 2016 .

[48]  D. Hilton,et al.  Inhibitors of Cytokine Signal Transduction* , 2004, Journal of Biological Chemistry.

[49]  L. Mao,et al.  Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. , 2007, International journal of oncology.

[50]  F. Bestvater,et al.  Impact of S100A8/A9 Expression on Prostate Cancer Progression In Vitro and In Vivo , 2014, Journal of cellular physiology.

[51]  W. Janzen,et al.  High Throughput Screening , 2016, Methods in Molecular Biology.

[52]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[53]  Mariano J. Alvarez,et al.  A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.

[54]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[55]  Andrea Califano,et al.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. , 2013, Cancer cell.

[56]  D. Slamon,et al.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  T. Leanderson,et al.  S100A9 Interaction with TLR4 Promotes Tumor Growth , 2012, PloS one.

[59]  Chris Sander,et al.  Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2 , 2011, Silence.

[60]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[61]  Roy M. Williams,et al.  S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression , 2011, Molecular Cancer Research.

[62]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[63]  Chris Wiggins,et al.  ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context , 2004, BMC Bioinformatics.

[64]  J. Isaacs,et al.  The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts , 2007, The Prostate.

[65]  D. Foell,et al.  RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis , 2008, Carcinogenesis.

[66]  J. Darnell,et al.  Validating Stat3 in cancer therapy , 2005, Nature Medicine.

[67]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[68]  Michael K. Wendt,et al.  STAT3 and epithelial–mesenchymal transitions in carcinomas , 2014, JAK-STAT.

[69]  L. Moreland,et al.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy , 2010, Drug design, development and therapy.

[70]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[71]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.